DK3094976T3 - Celleoverfladeprostatakræftantigen til diagnose - Google Patents

Celleoverfladeprostatakræftantigen til diagnose Download PDF

Info

Publication number
DK3094976T3
DK3094976T3 DK15737205.3T DK15737205T DK3094976T3 DK 3094976 T3 DK3094976 T3 DK 3094976T3 DK 15737205 T DK15737205 T DK 15737205T DK 3094976 T3 DK3094976 T3 DK 3094976T3
Authority
DK
Denmark
Prior art keywords
diagnosis
cell surface
craft
surface prostate
prostate
Prior art date
Application number
DK15737205.3T
Other languages
English (en)
Inventor
Bradley Walsh
Douglas Campbell
Fuenmayor Irene Justiniano
Aline Nocon
Julie Soon
Quach Truong
Sandra Wissmueller
Pamela Russell
Original Assignee
Minomic Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minomic Int Ltd filed Critical Minomic Int Ltd
Application granted granted Critical
Publication of DK3094976T3 publication Critical patent/DK3094976T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21077Semenogelase (3.4.21.77), i.e. prostate specific antigen or PSA or kallikrein 3
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433Serine endopeptidases (3.4.21)
    • G01N2333/96441Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455Kallikrein (3.4.21.34; 3.4.21.35)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
DK15737205.3T 2014-01-17 2015-01-16 Celleoverfladeprostatakræftantigen til diagnose DK3094976T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461928776P 2014-01-17 2014-01-17
PCT/AU2015/000018 WO2015106311A1 (en) 2014-01-17 2015-01-16 Cell surface prostate cancer antigen for diagnosis

Publications (1)

Publication Number Publication Date
DK3094976T3 true DK3094976T3 (da) 2020-06-22

Family

ID=53542211

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15737205.3T DK3094976T3 (da) 2014-01-17 2015-01-16 Celleoverfladeprostatakræftantigen til diagnose

Country Status (12)

Country Link
US (2) US10151754B2 (da)
EP (1) EP3094976B1 (da)
JP (2) JP6691060B2 (da)
KR (1) KR102366820B1 (da)
CN (1) CN106164672B (da)
AU (1) AU2015207665B2 (da)
CA (1) CA2936805C (da)
DK (1) DK3094976T3 (da)
ES (1) ES2803217T3 (da)
HK (1) HK1225791A1 (da)
SG (1) SG11201605784YA (da)
WO (1) WO2015106311A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3209686T3 (da) * 2014-10-23 2020-03-16 Glyp Holdings Pty Ltd Monoklonale anti-gpc-1-antistoffer og anvendelser deraf
EP3285805B1 (en) 2015-04-20 2021-05-26 GlyTherix Ltd Therapeutic antibodies and uses thereof
CN106053815B (zh) * 2016-07-01 2018-03-27 复旦大学附属中山医院 Gpc1作为肿瘤诊断标志物的用途
JPWO2018199318A1 (ja) * 2017-04-28 2020-03-12 国立大学法人高知大学 抗gpc−1抗体
CN107907684A (zh) * 2017-09-29 2018-04-13 何皓 一种基于多重荧光寿命分辨检测技术的前列腺癌早期诊断系统
CN111187350A (zh) * 2019-12-30 2020-05-22 西安英创生物技术有限公司 一种与磷脂酰肌醇蛋白聚糖-1结合的抗原结合蛋白
JP7053058B2 (ja) * 2020-05-28 2022-04-12 グリピー ホールディングス ピーティーワイ リミテッド グリピカンエピトープおよびその使用
WO2024075067A1 (en) * 2022-10-06 2024-04-11 Centro Di Riferimento Oncologico Cancer vaccine composition that comprises a host cell expressing glypican-1 (gpc-1)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (da) 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5622836A (en) 1989-05-24 1997-04-22 The University Of Sydney Monoclonal antibodies which recognize malignant cells from bladder carcinomas
US6116013A (en) 1998-01-02 2000-09-12 Siemens Westinghouse Power Corporation Bolted gas turbine combustor transition coupling
US7108986B2 (en) * 1998-10-16 2006-09-19 The Regents Of The University Of California Glypican-1 in human breast cancer
EP1439857B1 (en) 2001-10-12 2009-02-25 Schering Corporation USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES
AU2002330482A1 (en) * 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
CN102698267B (zh) * 2004-08-24 2017-07-21 中外制药株式会社 使用抗磷脂酰肌醇蛋白聚糖‑3抗体的辅助疗法
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7723043B2 (en) * 2006-01-04 2010-05-25 Picobella, Lp Methods for screening for prostate cancer
WO2008060607A2 (en) 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
WO2008092894A1 (en) * 2007-02-02 2008-08-07 Novartis Ag Modulators of sclerostin binding partners for treating bone-related disorders
WO2008140774A2 (en) * 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
KR101105428B1 (ko) * 2009-02-12 2012-01-17 경북대학교 산학협력단 글리피칸-3 단백질과 특이적으로 결합하는 펩타이드
WO2013119964A2 (en) * 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
WO2012151609A1 (en) * 2011-05-06 2012-11-15 Women's And Children's Health Research Institute Inc Method of treatment and prophylaxis of pathologies of the bone

Also Published As

Publication number Publication date
CA2936805A1 (en) 2015-07-23
EP3094976A4 (en) 2017-07-05
WO2015106311A1 (en) 2015-07-23
AU2015207665B2 (en) 2021-04-15
KR102366820B1 (ko) 2022-02-22
HK1225791A1 (zh) 2017-09-15
US20160349263A1 (en) 2016-12-01
JP2017504812A (ja) 2017-02-09
ES2803217T3 (es) 2021-01-25
CA2936805C (en) 2024-02-20
US20190120846A1 (en) 2019-04-25
CN106164672A (zh) 2016-11-23
EP3094976A1 (en) 2016-11-23
AU2015207665A1 (en) 2016-08-04
KR20160114088A (ko) 2016-10-04
JP6691060B2 (ja) 2020-04-28
US10151754B2 (en) 2018-12-11
JP2020060585A (ja) 2020-04-16
SG11201605784YA (en) 2016-08-30
EP3094976B1 (en) 2020-03-25
CN106164672B (zh) 2018-08-28

Similar Documents

Publication Publication Date Title
DK3560953T3 (da) Celle
DK3094976T3 (da) Celleoverfladeprostatakræftantigen til diagnose
DK3125898T3 (da) Farmakofor til trail-induktion
BR112017013841A2 (pt) solução oftálmica aquosa
DK3427323T3 (da) Brændselscelle
IL251948A0 (en) A floating structure
GB201409519D0 (en) Senescent cell biomarkers
DK3513192T3 (da) Celledødsbiomarkør
DK3145804T3 (da) Ubemandet overfladefartøj
FI20165848A (fi) Venttiililaite vaahdotuskennoja varten
ES2914082T8 (es) Procedimiento de generación de progenitores de células T
FI11194U1 (fi) Mittausjärjestely
JP2016096066A5 (ja) 燃料電池システム
FR3022880B1 (fr) Eolienne flottante
GB201418266D0 (en) Fuel cell assembly
FI20145079A (fi) Järjestely vesiaktiviteetteja varten
GB201413781D0 (en) Fuel cell
DE112015002240A5 (de) Wasserspringbrunnen
DK3154516T3 (da) Stabiliseret desmopressin
FI20146118A (fi) Katamaraani
ES1117755Y (es) Embarcación
GB201411625D0 (en) Fuel cell
FI20145453A (fi) Nestesäiliö
TH1601003659A (th) เรือเวเฟอร์
ES1137384Y (es) Tanque de flotacion